2023 World Conference on Lung Cancer (Posters)-EP12.01. Increased Progression Free Survival of Patients with EGFR positive mutation NSCLC Treated with Afatinib in Regard to Toxicity

EP12.01. Increased Progression Free Survival of Patients with EGFR positive mutation NSCLC Treated with Afatinib in Regard to Toxicity - PDF(Abstract)

Back to course

Pdf Summary

This study aimed to investigate the clinical risk factors affecting the progression-free survival (PFS) of patients with EGFR-positive mutation non-small cell lung cancer (NSCLC) who were treated with first-line afatinib in Indonesia. The study collected data from medical records of 103 patients from respiratory service centers nationwide between January 2017 and December 2021.<br /><br />The results showed that 90.3% of the patients had EGFR common mutations, and the median PFS was 11 months. Female patients had longer PFS compared to male patients, and patients with exon 19 deletion, never smoker status, and good ECOG performance status (PS) had the longest PFS. On the other hand, patients with poor ECOG PS had the shortest PFS.<br /><br />The study also found that poor ECOG PS significantly affected PFS, while other demographic characteristics such as gender, race, family history of cancer, history of tuberculosis, staging, pleural effusion, brain metastasis, EGFR mutations, and toxicities did not have a significant effect on PFS or overall survival.<br /><br />The findings suggest that afatinib is an effective first-line therapy for NSCLC patients with EGFR mutations, with tolerable toxicity and improved survival. Poor ECOG PS was identified as an independent factor associated with poor PFS in this patient population. The study provides valuable insights into the clinical factors that can influence treatment outcomes in EGFR-positive mutation NSCLC patients treated with afatinib.<br /><br />Overall, this research highlights the importance of considering the individual characteristics and performance status of patients in treatment decisions to optimize outcomes in EGFR-positive mutation NSCLC.

Asset Subtitle

Suryanti Pratiwi

Meta Tag

Speaker Suryanti Pratiwi

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

progression-free survival

EGFR-positive mutation

NSCLC

afatinib

Indonesia

ECOG performance status

exon 19 deletion

tolerable toxicity

clinical factors

treatment outcomes